CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Instagram Outage Disrupts Thousands of U.S. Users 
LUND, Sweden, April 28, 2016 --
Laquinimod
- The clinical Phase 3 study CONCERTO, 0.6 mg/day, in relapsing remitting multiple sclerosis (RRMS), with the aim to obtain market approval in the US and Europe, is proceeding according to plan. Study results are expected in the first half of 2017
- The clinical Phase 2 study ARPEGGIO for the treatment of primary progressive multiple sclerosis (PPMS) is proceeding according to plan
- The clinical Phase 2 study LEGATO-HD for the treatment of Huntington's disease is proceeding according to plan
- Extension studies with 0.6 mg laquinimod in patients from the Phase 3 studies ALLEGRO and BRAVO are proceeding according to plan
- As earlier communicated the highest dose groups in the clinical studies CONCERTO, ARPEGGIO and LEGATO-HD have been discontinued due to cardiovascular events
Tasquinimod
- In March 2016, it was announced that the company plans to develop tasquinimod to treat multiple myeloma and intends to seek a collaboration partner for the project
- An expanded analysis of the secondary endpoints in the 10TASQ10 study was presented at the ASCO GU Symposium in January 2016. The results showed that tasquinimod had positive effects on both radiographic and PSA-based endpoints. However, as previously communicated, overall survival (OS) was not extended, prompting the discontinuation of all further development within prostate cancer
ANYARA, Paquinimod (57-57) and SILC (ISI)
- Out-licensing activities are continuing
Financial summary
| MSEK | Jan. - Mar. | Full Year | |||
| 2016 | 2015 | 2015 | |||
| Net sales | 3.9 | 2.9 | 16.3 | ||
| Operating loss | -16.1 | -57.4 | -177.9 | ||
| Loss for the period | -16.8 | -58.0 | -193.5 | ||
| Loss per share, before and after dilution (SEK) | -0.19 | -0.64 | -2.15 | ||
| Cash and cash equivalents (at the end of the period) | 76.5 | 270.5 | 103.6 | ||
For further information, please contact:
Tomas Leanderson, President and CEO
Tel: +46 (0)46 19 20 95
Hans Kolam, CFO
Tel: +46 (0)46 19 20 44
Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46 19 20 00
Fax: +46 (0)46 19 11 05
The report is also available at www.activebiotech.com.
Active Biotech AB (publ) Interim report January - March 2016 http://hugin.info/1002/R/2007548/742184.pdf
HUG#2007548
